Appili Therapeutics

What Appili Therapeutics does

Appili Therapeutics is a Canadian biopharmaceutical company (TSX: APLI; OTCPink: APLIF) founded in 2015 and headquartered in Halifax, Nova Scotia, with a U.S. office in Frederick, Maryland. The company focuses exclusively on anti-infective drug development across three program categories: a commercial product (LIKMEZ/ATI-1501, an FDA-approved taste-masked metronidazole oral suspension commercialized via partner Saptalis Pharmaceuticals), government-funded biodefense vaccines (ATI-1701 live-attenuated tularemia vaccine under FDA Animal Rule; VXV-01 dual-antigen antifungal vaccine), and a tropical-disease asset (ATI-1801 topical paromomycin for cutaneous leishmaniasis). The portfolio is protected by issued patents (LIKMEZ coverage through 2039), FDA Orphan Drug Designation (ATI-1801), and potential Priority Review Voucher eligibility for ATI-1701 and ATI-1801.

Appili's business model is a hybrid of non-dilutive government contracting and licensed commercialization. The company secures substantial government funding from U.S. agencies — approximately US$14 million from USAFA/DTRA for ATI-1701 and up to US$40 million from NIAID for VXV-01 — to advance its vaccine pipeline without equity dilution. Commercial revenue derives from milestone payments and royalties paid by Saptalis Pharmaceuticals, which holds licensed rights to LIKMEZ across the U.S., Europe, and Latin America. Customer segments are concentrated in two groups: U.S. government agencies funding biodefense and medical countermeasure development, and the single commercialization partner for the only approved product.

The company operates with a small team (11–50 employees) and has reported recurring net losses (approximately US$3.8–4.2 million in recent fiscal years), with capital supplemented by bridge loans (Bloom Burton & Co.) and modest non-brokered private placements. A proposed acquisition by Aditxt Inc. that received 99.79% shareholder approval and court sanction was formally terminated in May 2025, and Appili continues operating as an independent public entity with a market capitalization of approximately C$1.88 million as of February 2026.

Name

Appili Therapeutics

Legal name

Appili Therapeutics Inc.

Website

https://appilitherapeutics.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Appili Therapeutics is a Canadian biopharmaceutical company developing anti-infective drugs, including an FDA-approved taste-masked metronidazole oral suspension (LIKMEZ) and a pipeline of biodefense and tropical-disease vaccines funded largely by U.S. government agencies and out-licensed for commercialization.

Ownership category

akta.pro rank

Product category

Anti-infective Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Anti-infective pharmaceuticals
• Biodefense vaccine development
• Infectious disease therapeutics
• Live-attenuated vaccines
• Orphan drug development

Headquarters

HQ city

Halifax

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Product Licensing and Royalties: Appili earns milestone payments and royalties from commercialization partner Saptalis Pharmaceuticals for LIKMEZ sales in the U.S. and other territories. Patent coverage extends through 2039.
2. Government Non-Dilutive Funding: The company secures significant government funding for vaccine development programs including US$14 million from USAFA/DTRA for ATI-1701 and US$40 million NIAID contract for VXV-01 fungal vaccine, supporting development through regulatory submissions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Appili Therapeutics is a publicly traded anti-infective biopharmaceutical company that develops and reformulates therapeutics and vaccines for unmet needs in infectious disease and biodefense. Its commercial-stage product, LIKMEZ (ATI-1501), is an FDA-approved taste-masked oral suspension of metronidazole for the treatment of anaerobic bacterial and parasitic infections. The pipeline includes ATI-1701, a live-attenuated tularemia vaccine candidate supported by U.S. biodefense funding, ATI-1801, a topical paromomycin for cutaneous leishmaniasis, VXV-01, a fungal vaccine candidate, and ATI-2307, an investigational antifungal.

Product overview

Appili Therapeutics is an infectious disease biopharmaceutical company with a portfolio of anti-infective products. The company has one FDA-approved commercial product (LIKMEZ/ATI-1501, a taste-masked metronidazole oral suspension) and multiple pipeline candidates including ATI-1701 (biodefense vaccine for tularemia), ATI-1801 (topical paromomycin for cutaneous leishmaniasis), VXV-01 (fungal vaccine), and ATI-2307 (antifungal). Products target infectious diseases, biothreat pathogens, and unmet medical needs in antimicrobial treatments.

Differentiator

Problem solved

Functional benefit

Brands

• LIKMEZ: FDA-approved taste-masked liquid oral suspension of metronidazole for treating serious anaerobic and protozoal infections. Trademark of Saptalis Pharmaceuticals, LLC.

Products and services

• LIKMEZ (ATI-1501) FDA-approved taste-masked liquid formulation of metronidazole for the treatment of anaerobic bacterial and parasitic infections in patients who have difficulty swallowing tablets; commercialized through Saptalis Pharmaceuticals.
• ATI-1701 Live-attenuated tularemia vaccine candidate designed as a biodefense countermeasure for the U.S. government against Francisella tularensis, the causative agent of tularemia.
• ATI-1801 Topical paromomycin reformulation for the treatment of cutaneous leishmaniasis, an orphan indication; received FDA Orphan Drug Designation.
• VXV-01 Dual-antigen fungal vaccine candidate targeting Coccidioides (Valley Fever), being developed as a non-dilutive-funded pipeline asset.
• ATI-2307 Investigational antifungal small molecule in early-stage development for difficult-to-treat fungal infections.

Quantifiable outcome

• LIKMEZ achieved FDA approval September 2023, launched commercially November 2023
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Vitalex BiosciencescoreStrategic or Co-development Partner · 1 October 2025Subcontractor for US$40 million NIAID contract to develop VXV-01 fungal vaccine. Appili holds exclusive option to acquire worldwide rights to VXV-01. Partnership advances dual-antigen vaccine targeting drug-resistant Candida species through Phase 1 trials.
• Saptalis Pharmaceuticals LLCcoreOEM/ Whitelabel/ Licensing Partner · 25 September 2023Licensed commercial rights to LIKMEZ (ATI-1501) for U.S., Europe, and Latin America markets. Saptalis is responsible for manufacturing, FDA-approved formulation using Appili's taste-masking technology, and commercialization. Appili receives milestone payments and royalties on sales.
• FUJIFILMminorStrategic or Co-development Partner · 20 September 2021Agreement and funding support for clinical trial evaluating Avigan/Reeqonus for COVID-19 patients, expediting completion of Phase 3 study of the oral antiviral medicine.
• U.S. Army Medical Materiel Development Activity (USAMMDA)coreOEM/ Whitelabel/ Licensing PartnerLicensed full clinical dossier for ATI-1801 from USAMMDA, including results from randomized, double-blind, vehicle-controlled Phase 3 study in Tunisia demonstrating safety and efficacy for cutaneous leishmaniasis treatment.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Soligenix: Small-cap biopharmaceutical company with both biodefense (ricin vaccine, thermo-stable technology) and specialty infectious disease programs. Closest size, structure, and pipeline composition peer to Appili.
• Paratek Pharmaceuticals: Anti-infective specialty pharma (Nuzyra/omadacycline) targeting resistant bacterial infections — comparable specialty anti-infective commercial model and government contracting approach to Appili.
• Nabriva Therapeutics: Small anti-infective specialty pharma focused on pleuromutilin antibiotics for community-acquired pneumonia. Similar specialty anti-infective positioning, public small-cap status, and commercial-stage dynamics.
• Iterum Therapeutics: Small-cap anti-infective biotech developing oral sulopenem for resistant infections. Comparable size, public micro-cap status, and anti-infective focus area to Appili.
• Bavarian Nordic: Develops live-attenuated biodefense vaccines including Jynneos (smallpox/mpox) and Ebola vaccine — directly comparable vaccine platform and government stockpile customer profile to Appili's ATI-1701 and VXV-01.
• BioCryst Pharmaceuticals: Anti-infective specialty pharma developing antivirals (influenza, COVID) and antifungals — directly comparable therapeutic focus area to Appili's LIKMEZ, ATI-2307, and VXV-01 programs.
• SIGA Technologies: Small-cap biodefense specialty pharma with Tpoxx (oral tecovirimat) for smallpox — the closest pure-play biodefense antiviral comparable to Appili's ATI-1701 tularemia program. Similar revenue scale and government contracting profile.

Broad incumbents

• Emergent BioSolutions: Largest pure-play biodefense company (anthrax vaccines, smallpox, NARCAN) selling into the same US government stockpiling channels Appili targets with ATI-1701. Larger and more diversified but overlapping customer set.
• Dr. Reddy's Laboratories: Large generic pharmaceutical manufacturer producing generic metronidazole formulations that compete directly with LIKMEZ. Relevant commercial competitor and benchmark for Appili's taste-masked liquid product positioning.

Emerging players

• Tonix Pharmaceuticals: Clinical-stage biopharma with infectious disease vaccine programs (including biodefense candidates) and central nervous system portfolio. Comparable small-cap public status and partial overlap in biodefense vaccine development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/appili
• LinkedInlinkedin.com/company/appili-therapeutics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds18 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Appili Therapeutics